SEC filing record
Primary Source · SEC.gov

Crinetics Pharmaceuticals, Inc.

2024 vintageSecurities Exchange Act of 1934Filing record

Built from the SEC filing index the day the filing landed. The figures below are the issuer's own from Form 15 / Schedule TO; AltStreet's analysis, sponsor link and data flags follow when the entity is enriched.

Latest signalExchange Act deregistrationForm 15-12G · 2026-09-113 events: 1 exchange act deregistration, 1 new form d filer, 1 large raiseLast filing 2026-09-11

Raised

$350M

Investors

36

Min Invest

None stated

AltStreet Verified Issuer badge

Is this your company or fund? Claim this page free, or verify it and carry the Verified Issuer mark.

What this filing shows

·

Every sentence is a value as filed on SEC Form D

Crinetics Pharmaceuticals, Inc. is an entity organized in Delaware that filed a Form D with the SEC on September 11, 2026. The offering claims Securities Exchange Act of 1934. Crinetics Pharmaceuticals, Inc. reported $350,000,028 sold from 36 investors as of the Form D filed September 11, 2026. The Form D names LEERINK PARTNERS LLC (CRD 39011), associated with None; PIPER SANDLER & CO. (CRD 665), associated with None; ROBERT W. BAIRD & CO. INCORPORATED (CRD 8158), associated with None; CITIZENS JMP SECURITIES, LLC (CRD 22208), associated with None and 2 others as recipients of sales compensation soliciting in all states. The issuer's address of record is 6055 Lusk Blvd., San Diego, CA 92121.

EDGAR Filing Data

Form 15 / Schedule TO — Primary Source

View on SEC.gov
CIK Number0001658247
Entity NameCrinetics Pharmaceuticals, Inc.
ExemptionSecurities Exchange Act of 1934
Entity Type—
Jurisdiction of OrganizationDelaware
Issuer Address6055 Lusk Blvd., San Diego, CA 92121
Phone(858) 450-6464
Industry / Fund Type—
Securities Type—
First Sale Date—
Filing DateSeptember 11, 2026
Accession Number0001140361-26-036281
Total Offering Amount$350,000,028
Total Amount Sold$350,000,028
Total Investors36
Minimum Investment$0 (no stated minimum)
Offering Duration—
State (Issuer Address)CA
Amendment Count4 filings on record

Filings on Record

Every filing AltStreet's ledger holds for this CIK, newest first. Each opens the SEC archive folder.

In the Terminal

Filing events

3

latest Sep 11, 2026

Critical / warning

0 / 3

0 watch · 0 info

Statements extracted

0

none on file

NAV prints

0

none on file

Offering chains

2

lapsed, closed

Latest event Exchange act deregistration · Sep 11, 2026

SEC.gov
Open in the terminal Watch this issuerInvestor $149/mo unlocks the values; Pro $349/mo adds the universe.

Investor

  • 3 filing events with values and deltas, latest 2026-09-11, and alerts on the next one
  • 2 offering timelines: velocity, share raised, first-sale lag, stalled flags

Pro

  • This issuer against its cohort: rank by velocity and share raised among offerings filed the same quarter
  • The same events, statements and NAV moves across every issuer, screenable, with unlimited watches and CSV

Counts and dates above are the free record. The values, the series and the comparisons are the seat. Loading your view…

Related Persons (Form D)

Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.

Item 3 changed on the Form D filed 2024-03-11: 11 related persons added and 6 removed against the filing of 2018-02-23; 13 now listed. The names are in the Terminal feed.

RICHARD SCOTT STRUTHERS, PhD

Executive Officer, Director · SAN DIEGO, CA

MARC SCOTT WILSON

Executive Officer · SAN DIEGO, CA

WENDELL SCOTT WIERENGA, PhD

Director · SAN DIEGO, CA

CAMILLE SCOTT BEDROSIAN, M.D.

Director · SAN DIEGO, CA

CAREN SCOTT DEARDORF

Director · SAN DIEGO, CA

MATTHEW SCOTT FUST

Director · SAN DIEGO, CA

WESTON SCOTT NICHOLS, PhD

Director · SAN DIEGO, CA

STEPHANIE SCOTT OKEY

Director · SAN DIEGO, CA

ROGERIO VIVALDI COELHO, M.D.

Director · SAN DIEGO, CA

STEPHEN VIVALDI BETZ

Executive Officer · SAN DIEGO, CA

DANA VIVALDI PIZZUTI

Executive Officer · SAN DIEGO, CA

JEFF VIVALDI KNIGHT

Executive Officer · SAN DIEGO, CA

JAMES VIVALDI HASSARD

Executive Officer · SAN DIEGO, CA

Placement Agents and Sales Compensation (Form D)

Who the issuer reported paying to sell the securities (Form D Item 12), with the FINRA registration number the filer gave. Source: SEC.gov.

LEERINK PARTNERS LLCCRD 39011 on BrokerCheck

Associated broker-dealer: None · NEW YORK, NY · Soliciting in all states

PIPER SANDLER & CO.CRD 665 on BrokerCheck

Associated broker-dealer: None · MINNEAPOLIS, MN · Soliciting in all states

ROBERT W. BAIRD & CO. INCORPORATEDCRD 8158 on BrokerCheck

Associated broker-dealer: None · MILWAUKEE, WI · Soliciting in all states

CITIZENS JMP SECURITIES, LLCCRD 22208 on BrokerCheck

Associated broker-dealer: None · SAN FRANCISCO, CA · Soliciting in all states

H.C. WAINWRIGHT & CO., LLCCRD 375 on BrokerCheck

Associated broker-dealer: None · NEW YORK, NY · Soliciting in all states

LIFESCI CAPITAL, LLCCRD 168404 on BrokerCheck

Associated broker-dealer: None · New York, NY · Soliciting in all states

Questions About Crinetics Pharmaceuticals, Inc.

Each answer is built from the values on the SEC filing and the AltStreet ledger, not from the issuer's marketing.

What is Crinetics Pharmaceuticals, Inc.?

Crinetics Pharmaceuticals, Inc. is an issuer that filed a Form D with the SEC on September 11, 2026. The filing claims Securities Exchange Act of 1934.

Is Crinetics Pharmaceuticals, Inc. legit?

AltStreet does not rate legitimacy; it reports the public record. Crinetics Pharmaceuticals, Inc. filed a Form D with the SEC on September 11, 2026 claiming Securities Exchange Act of 1934. A Form D is a notice of an exempt offering, not a review or approval of it. The newest notice reports $350,000,028 sold to 36 investors. AltStreet's enforcement record (SEC, FINRA and state actions) shows no action naming the issuer as of today. Before investing, confirm the filing on EDGAR, check the seller's registration on FINRA BrokerCheck, and read the offering documents, which a Form D does not include.

Is Crinetics Pharmaceuticals, Inc. registered with or approved by the SEC?

No. A Form D is a notice that an issuer is selling securities under an exemption from registration, and the SEC does not review, approve, or pass on the merits of the offering. The filing shows that Crinetics Pharmaceuticals, Inc. claimed Securities Exchange Act of 1934 and disclosed the items the form requires, such as the amount sold, the minimum investment, related persons, and anyone paid to sell the securities. It does not verify the issuer's claims or its business.

How much has Crinetics Pharmaceuticals, Inc. raised?

Crinetics Pharmaceuticals, Inc. reported $350,000,028 sold from 36 investors as of the Form D filed September 11, 2026.

Who is selling Crinetics Pharmaceuticals, Inc. and how are they paid?

The Form D names LEERINK PARTNERS LLC (CRD 39011), associated with None; PIPER SANDLER & CO. (CRD 665), associated with None; ROBERT W. BAIRD & CO. INCORPORATED (CRD 8158), associated with None; CITIZENS JMP SECURITIES, LLC (CRD 22208), associated with None and 2 others as recipients of sales compensation soliciting in all states.

Who is behind Crinetics Pharmaceuticals, Inc.?

The Form D lists 13 related persons: RICHARD SCOTT STRUTHERS, PhD, executive officer, director; MARC SCOTT WILSON, executive officer; WENDELL SCOTT WIERENGA, PhD, director; CAMILLE SCOTT BEDROSIAN, M.D., director; CAREN SCOTT DEARDORF, director; MATTHEW SCOTT FUST, director; WESTON SCOTT NICHOLS, PhD, director; STEPHANIE SCOTT OKEY, director, and 5 more. Form D Item 3 requires executive officers, directors, and promoters of the issuer to be listed.

Where is Crinetics Pharmaceuticals, Inc. located?

The issuer's address on its SEC filings is 6055 Lusk Blvd., San Diego, CA 92121. Its phone number of record is 858-450-6464. It is organized under the laws of Delaware.

AltStreet Verified Issuer badge

Is this your company or fund?

Free claim: add your contact details, website, team and a description to this page. The filed facts stay as filed.

Verified Issuer, $480 a year: AltStreet checks the identity of your company and the authority of the person claiming it against your filings, confirms your contact details on a stated date and again at each renewal, and marks the page so people researching you find a current, attributed profile beside the public filing record. It is not a review of any offering.

Data Methodology

Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.